USSTOCK.TODAY
Regular Market
Log in Sign up

AstraZeneca Fails Phase 3 Trial for Rare Bone Disease Treatment

Clinical Trials Arena ·

AZN Astrazeneca plc
$162.03 +3.99%
View chart & analysis →
  1. 1AstraZeneca's efzimfotase alfa failed to demonstrate a significant benefit over placebo in a Phase 3 trial for patients with HPP, a rare bone disease.
  2. 2The percentage of patients treated with efzimfotase alfa who achieved a Minimally Clinically Important Difference (MCID) was 45.2%.
  3. 3BioMarin acquired Alesta Therapeutics and its candidate ALE1 for $490 million in August 2026.

So what's the key point?

AstraZeneca did not show enough effectiveness in the final trial for a rare bone disease treatment. BioMarin purchased Alesta Therapeutics and its candidate for $490 million.

Source Clinical Trials Arena · View original ↗

Related 3-line summaries

AstraZeneca signs AI drug discovery deal with Insitro worth up to $1.5 billion TIKR +2 · 2h agoAstraZeneca opens new $1 billion R&D center in Massachusetts Quartz +2 · Oct 6OCC imposes $350 million fine on American Express National Bank for inadequate anti-money laundering controls Electronic Payments +2 · 2d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news